60 Degrees Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
SXTP Nasdaq 2834 www.60degreespharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for 60 Degrees Pharmaceuticals, Inc.

60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria - Jul 17th, 2025 6:01 am
60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering - Jul 16th, 2025 2:01 pm
60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering - Jul 15th, 2025 7:10 am
60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion - Jul 15th, 2025 5:01 am
60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025 - Jul 14th, 2025 2:01 pm
60 Degrees Pharmaceuticals and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Jun 6th, 2025 7:00 am
60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format - Jun 4th, 2025 6:56 am
60 Degrees announces results from an insurance claims analysis on babesiosis - Jun 4th, 2025 6:55 am
Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals - Jun 3rd, 2025 6:49 am
60 Degrees Pharmaceuticals Announces First Quarter 2025 Results - May 15th, 2025 2:31 pm
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates - May 8th, 2025 3:10 pm
Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey - Apr 22nd, 2025 6:44 am
Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday? - Apr 10th, 2025 7:24 am
Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21 - Apr 10th, 2025 6:31 am
60 Degrees and Yale to progress tafenoquin for babesiosis - Apr 9th, 2025 8:14 am
Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health - Apr 8th, 2025 6:31 am
60 Degrees Pharmaceuticals Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Mar 29th, 2025 7:27 am
60 Degrees Pharmaceuticals Announces 2024 Annual Results - Mar 28th, 2025 4:59 am
60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Feb 21st, 2025 7:00 am
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split - Feb 20th, 2025 8:36 am